Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ultitar CS is a topical combination therapy formulated as an ointment or lotion for the treatment of chronic inflammatory skin conditions, primarily psoriasis, eczema, and seborrheic dermatitis. It contains three active ingredients: clobetasol propionate, a highly potent corticosteroid that suppresses inflammatory and immune responses; salicylic acid, a keratolytic agent that softens and promotes the shedding of thick, scaly skin; and coal tar, which slows excessive skin cell growth and provides antipruritic and anti-inflammatory benefits. Together, these components work synergistically to reduce redness, swelling, itching, and scaling, while improving skin texture and facilitating deeper penetration of the active ingredients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ultitar CS.